Skip to main content
Top
Published in: Drug Safety 9/2005

01-09-2005 | Current Opinion

When Should Vaccination Be Contraindicated in Children?

Authors: Laura Lane, Arlene Reynolds, Dr Mary Ramsay

Published in: Drug Safety | Issue 9/2005

Login to get access

Abstract

No child should be denied immunisation without serious consideration given to the consequences. In the past, many contraindications to vaccination were based on theoretical concerns. These concerns often assumed an immunoallergic mechanism for adverse reactions, whereas many such events are often due to other causes. Other contraindications were based on evidence of excess risk, but this risk was not always balanced against the higher risk of disease. Therefore, contraindications often varied between countries and over time.
In recent years, the widespread availability of less reactogenic vaccines and the common use of combined preparations have prompted a review of contraindications in many countries. Accumulated experience worldwide has allowed the list of conditions that contraindicate vaccination to be reduced. The international consensus now is that there are very few situations in which a child should not be immunised and the only true contraindication applicable to all vaccines is a history of anaphylaxis to a vaccine component or following a previous dose of the vaccine. Health professionals should feel confident in accepting national recommendations and, if in doubt, should refer children for an expert opinion, rather than deny a child protection against a serious infection.
Literature
1.
go back to reference UK Departments of Health. Immunisation against infectious disease: updated chapters on diphtheria, Hib, pertussis, polio and tetanus. London: Department of Health, 2004 UK Departments of Health. Immunisation against infectious disease: updated chapters on diphtheria, Hib, pertussis, polio and tetanus. London: Department of Health, 2004
2.
go back to reference National Health and Medical Research Council. Australian immunisation handbook. 8th ed. Canberra: Commonwealth of Australia, 2003 National Health and Medical Research Council. Australian immunisation handbook. 8th ed. Canberra: Commonwealth of Australia, 2003
3.
go back to reference National Immunization Program, Centers for Disease Control and Prevention, US Department of Health and Human Services. Epidemiology and prevention of vaccine preventable diseases. 8th ed., 2004 [online]. Available from URL: http://www.cdc.gov/nip/publications/pink/def_pink_full.htm [Accessed 2004 Oct 26] National Immunization Program, Centers for Disease Control and Prevention, US Department of Health and Human Services. Epidemiology and prevention of vaccine preventable diseases. 8th ed., 2004 [online]. Available from URL: http://​www.​cdc.​gov/​nip/​publications/​pink/​def_​pink_​full.​htm [Accessed 2004 Oct 26]
4.
go back to reference Canadian Medical Association. Canadian immunization guide. 6th ed., 2002 [online]. Available from URL: http://www.phacaspc.gc.ca/publicat/cig-gci/pdf/cdn_immuniz_guide-2002-6.pdf [Accessed 2004 Oct 26] Canadian Medical Association. Canadian immunization guide. 6th ed., 2002 [online]. Available from URL: http://​www.​phacaspc.​gc.​ca/​publicat/​cig-gci/​pdf/​cdn_​immuniz_​guide-2002-6.​pdf [Accessed 2004 Oct 26]
5.
go back to reference UK Departments of Health. Immunisation against infectious disease. London: HMSO, 1996 UK Departments of Health. Immunisation against infectious disease. London: HMSO, 1996
6.
go back to reference Wood D, Halfon N, Pereyra M, et al. Knowledge of the childhood immunisation schedule and of contraindications to vaccinate by private and public providers in Los Angeles. Pediatr Infect Dis J 1996 Feb; 15(2): 140–5PubMedCrossRef Wood D, Halfon N, Pereyra M, et al. Knowledge of the childhood immunisation schedule and of contraindications to vaccinate by private and public providers in Los Angeles. Pediatr Infect Dis J 1996 Feb; 15(2): 140–5PubMedCrossRef
7.
go back to reference Cohen NJ, Lauderdale DS, Shete PB, et al. Physician knowledge of catch-up regimens and contraindications for childhood immunizations. Pediatrics 2003 May; 111(5): 925–32PubMedCrossRef Cohen NJ, Lauderdale DS, Shete PB, et al. Physician knowledge of catch-up regimens and contraindications for childhood immunizations. Pediatrics 2003 May; 111(5): 925–32PubMedCrossRef
8.
go back to reference Ponvert C, Scheinmann P. Vaccine allergy and pseudo-allergy. Eur J Dermatol 2003 Jan-Feb; 13(1): 10–5PubMed Ponvert C, Scheinmann P. Vaccine allergy and pseudo-allergy. Eur J Dermatol 2003 Jan-Feb; 13(1): 10–5PubMed
9.
go back to reference Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003 Oct; 112(4): 815–20PubMedCrossRef Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003 Oct; 112(4): 815–20PubMedCrossRef
10.
go back to reference Khakoo GA, Lack G. Recommendations for using MMR vaccine in children allergic to eggs. BMJ 2000; 320: 929–32CrossRef Khakoo GA, Lack G. Recommendations for using MMR vaccine in children allergic to eggs. BMJ 2000; 320: 929–32CrossRef
11.
go back to reference Andrews RM, Kempe AE, Sinn KK, et al. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med J Aust 1998 May 18; 168(10): 491–4PubMed Andrews RM, Kempe AE, Sinn KK, et al. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med J Aust 1998 May 18; 168(10): 491–4PubMed
12.
go back to reference James JM, Burks AW, Roberson PK, et al. Safe administration of measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262–6PubMedCrossRef James JM, Burks AW, Roberson PK, et al. Safe administration of measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262–6PubMedCrossRef
13.
go back to reference Centers for Disease Control and Prevention. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47: 1–57 Centers for Disease Control and Prevention. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47: 1–57
14.
go back to reference Fox A, Lack G. Egg allergy and MMR vaccination. Br J Gen Pract 2003 Oct; 55: 801–2 Fox A, Lack G. Egg allergy and MMR vaccination. Br J Gen Pract 2003 Oct; 55: 801–2
15.
go back to reference Patja A, Makinen-Kiljunen S, Davidkin I, et al. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001 Feb; 107(2): E27PubMedCrossRef Patja A, Makinen-Kiljunen S, Davidkin I, et al. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001 Feb; 107(2): E27PubMedCrossRef
16.
go back to reference Rietschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine [letter]. JAMA 1981 Feb 13; 245: 571PubMedCrossRef Rietschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine [letter]. JAMA 1981 Feb 13; 245: 571PubMedCrossRef
17.
go back to reference Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis 1988; 18: 229–33PubMedCrossRef Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis 1988; 18: 229–33PubMedCrossRef
18.
go back to reference Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004 Feb 1; 4(2): 84–90PubMedCrossRef Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004 Feb 1; 4(2): 84–90PubMedCrossRef
19.
20.
go back to reference Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy [letter]. Lancet 1991 Feb 9; 337: 365PubMedCrossRef Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy [letter]. Lancet 1991 Feb 9; 337: 365PubMedCrossRef
21.
go back to reference Madaan A, Maddox DE. Vaccine allergy: diagnosis and management. Immunol Allergy Clin North Am 2003 Nov; 23(4): 555–88PubMedCrossRef Madaan A, Maddox DE. Vaccine allergy: diagnosis and management. Immunol Allergy Clin North Am 2003 Nov; 23(4): 555–88PubMedCrossRef
22.
go back to reference Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650–60PubMed Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650–60PubMed
23.
go back to reference Cherry JD. Comparative efficacy of acellular pertussis vaccines; an analysis of recent trials. Pediatric Infect Dis J 1997; 16(4 Suppl.): S90–6CrossRef Cherry JD. Comparative efficacy of acellular pertussis vaccines; an analysis of recent trials. Pediatric Infect Dis J 1997; 16(4 Suppl.): S90–6CrossRef
24.
go back to reference Baraff LJ, Cherry JD, Cody CL, et al. DTP vaccine reactions: effect of prior reactions on subsequent reactions. Dev Biol Stand 1985; 61: 423–8PubMed Baraff LJ, Cherry JD, Cody CL, et al. DTP vaccine reactions: effect of prior reactions on subsequent reactions. Dev Biol Stand 1985; 61: 423–8PubMed
25.
go back to reference Verschoor PL, Wilschut JT, de Jonge GA, et al. Frequent symptoms after DTPP vaccinations. Arch Dis Child 1991 Dec; 66(12): 1408–12PubMedCrossRef Verschoor PL, Wilschut JT, de Jonge GA, et al. Frequent symptoms after DTPP vaccinations. Arch Dis Child 1991 Dec; 66(12): 1408–12PubMedCrossRef
26.
go back to reference Deloria MA, Blackwelder WC, Decker MD, et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995 Sep; 96(3 Pt 2): 592–4PubMed Deloria MA, Blackwelder WC, Decker MD, et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995 Sep; 96(3 Pt 2): 592–4PubMed
27.
go back to reference Long S, Deforest A, Smith D, et al. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990 Mar 3; 85(3): 294–302PubMed Long S, Deforest A, Smith D, et al. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990 Mar 3; 85(3): 294–302PubMed
28.
go back to reference Miller E. Vaccine safety surveillance. In: Talbot J, Waller P, editors. Stephens’ detection of new adverse drug reactions. 5th ed. Chichester: John Wiley and Sons Ltd, 2004: 571–590 Miller E. Vaccine safety surveillance. In: Talbot J, Waller P, editors. Stephens’ detection of new adverse drug reactions. 5th ed. Chichester: John Wiley and Sons Ltd, 2004: 571–590
29.
go back to reference National Advisory Committee on Immunization. Canadian immunization guide. 5th ed. Ottawa, Canada: Minister of Public Works and Government, 1998 National Advisory Committee on Immunization. Canadian immunization guide. 5th ed. Ottawa, Canada: Minister of Public Works and Government, 1998
30.
go back to reference Baraff LJ, Manclark CR, Cherry JD, et al. Analysis of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage weight gain. Pediatr Infect Dis J 1989; 8: 502–7PubMedCrossRef Baraff LJ, Manclark CR, Cherry JD, et al. Analysis of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage weight gain. Pediatr Infect Dis J 1989; 8: 502–7PubMedCrossRef
31.
go back to reference Gold M, Goodwin H, Botham S, et al. Re-vaccination of 421 children with a past history of an adverse reaction in a special immunisation service. Arch Dis Child 2000; 83: 128–31PubMedCrossRef Gold M, Goodwin H, Botham S, et al. Re-vaccination of 421 children with a past history of an adverse reaction in a special immunisation service. Arch Dis Child 2000; 83: 128–31PubMedCrossRef
32.
go back to reference Vermeer-de-Bondt PE, Labadie J, Rumke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998 Mar 21; 316: 902–3PubMedCrossRef Vermeer-de-Bondt PE, Labadie J, Rumke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998 Mar 21; 316: 902–3PubMedCrossRef
33.
go back to reference Andrews RM, Kempe AE, Sinn KK, et al. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med J Aust 1998; 168: 491–4PubMed Andrews RM, Kempe AE, Sinn KK, et al. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med J Aust 1998; 168: 491–4PubMed
34.
go back to reference Cherry JD. Comparative efficacy of acellular pertussis vaccines; an analysis of recent trials. Pediatr Infect Dis J 1997; 16(4 Suppl.): S90–6PubMed Cherry JD. Comparative efficacy of acellular pertussis vaccines; an analysis of recent trials. Pediatr Infect Dis J 1997; 16(4 Suppl.): S90–6PubMed
35.
go back to reference Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular-pertussis-tetanusdiphtheria vaccines. Pediatrics 2000 Jan; 105(1): e12PubMedCrossRef Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular-pertussis-tetanusdiphtheria vaccines. Pediatrics 2000 Jan; 105(1): e12PubMedCrossRef
36.
go back to reference Tozzi AE, Olin P. Common side effects in the Italian and Stockholm I trials. Dev Biol Stand 1997; 89: 105–8PubMed Tozzi AE, Olin P. Common side effects in the Italian and Stockholm I trials. Dev Biol Stand 1997; 89: 105–8PubMed
37.
go back to reference Jefferson T, Rudin M, Di Pietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003 May 16; 21(17-18): 2003–14PubMedCrossRef Jefferson T, Rudin M, Di Pietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003 May 16; 21(17-18): 2003–14PubMedCrossRef
38.
go back to reference Scheifle DW, Halperin SA, CPS/Health Canada, et al. Immunization Monitoring Programme. Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003 Jul; 14(3): 213–9CrossRef Scheifle DW, Halperin SA, CPS/Health Canada, et al. Immunization Monitoring Programme. Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003 Jul; 14(3): 213–9CrossRef
39.
go back to reference Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventative measures. Recommendations of the Immunization Practices Committee (ACIP). MMWR 1991; 40 (RR-10): 1–28 Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventative measures. Recommendations of the Immunization Practices Committee (ACIP). MMWR 1991; 40 (RR-10): 1–28
40.
go back to reference Pollock TM, Miller E, Mortimer JY, et al. Post-vaccination symptoms following DTP and DT vaccination. Dev Biol Stand 1985; 61: 407–10PubMed Pollock TM, Miller E, Mortimer JY, et al. Post-vaccination symptoms following DTP and DT vaccination. Dev Biol Stand 1985; 61: 407–10PubMed
41.
go back to reference Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 2001 Apr 6; 19(20-22): 2924–31PubMedCrossRef Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 2001 Apr 6; 19(20-22): 2924–31PubMedCrossRef
42.
go back to reference Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996 Dec; 174(6): 1360–3PubMedCrossRef Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996 Dec; 174(6): 1360–3PubMedCrossRef
43.
go back to reference Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 1995 Nov; 13(16): 1547–50PubMedCrossRef Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 1995 Nov; 13(16): 1547–50PubMedCrossRef
44.
go back to reference Collier LH, Polakoff S, Mortimer J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979 Jun 30; I(8131): 1364–8CrossRef Collier LH, Polakoff S, Mortimer J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979 Jun 30; I(8131): 1364–8CrossRef
45.
go back to reference Halperin SA, Scheifele D, Mills E, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003 Jun 2; 21(19-20): 2298–306PubMedCrossRef Halperin SA, Scheifele D, Mills E, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003 Jun 2; 21(19-20): 2298–306PubMedCrossRef
46.
go back to reference Southern J, Dean S, Ashton L, et al. Effect of prior polysaccharide vaccination on magnitude, duration and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004 Nov; 11(6): 1100–4PubMed Southern J, Dean S, Ashton L, et al. Effect of prior polysaccharide vaccination on magnitude, duration and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004 Nov; 11(6): 1100–4PubMed
47.
go back to reference Jacobs RL, Lowe RS, Lanier BQ. Adverse reactions to tetanus toxoid. JAMA 1982 Jan 1; 247(1): 40–2PubMedCrossRef Jacobs RL, Lowe RS, Lanier BQ. Adverse reactions to tetanus toxoid. JAMA 1982 Jan 1; 247(1): 40–2PubMedCrossRef
48.
go back to reference Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions and dose. Pediatrics 1984 Jan; 73(1): 31–6PubMed Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions and dose. Pediatrics 1984 Jan; 73(1): 31–6PubMed
49.
go back to reference Stetler HC, Orenstein WA, Bart KJ, et al. History of convulsions and use of pertussis vaccine. J Pediatr 1985 Aug; 107(2): 175–9PubMedCrossRef Stetler HC, Orenstein WA, Bart KJ, et al. History of convulsions and use of pertussis vaccine. J Pediatr 1985 Aug; 107(2): 175–9PubMedCrossRef
50.
go back to reference Baraff LJ, Shields WD, Beckwith L, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 1988 Jun; 81(6): 789–94PubMed Baraff LJ, Shields WD, Beckwith L, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 1988 Jun; 81(6): 789–94PubMed
51.
go back to reference Miller D, Wadsworth J, Diamond J, et al. Pertussis vaccine and whooping cough as risk factors in acute neurological illness and death in young children. Dev Biol Stand 1985; 61: 389–94PubMed Miller D, Wadsworth J, Diamond J, et al. Pertussis vaccine and whooping cough as risk factors in acute neurological illness and death in young children. Dev Biol Stand 1985; 61: 389–94PubMed
52.
go back to reference Ramsay M, Begg N, Holland B, et al. Pertussis immunisation in children with a family or personal history of convulsions: a review of children referred for specialist advice. Health Trends 1994; 26(1): 23–4PubMed Ramsay M, Begg N, Holland B, et al. Pertussis immunisation in children with a family or personal history of convulsions: a review of children referred for specialist advice. Health Trends 1994; 26(1): 23–4PubMed
53.
go back to reference Miyake S, Fujita M, Endo C, et al. Recurrence of febrile convulsions after the first diphtheria-pertussis-tetanus vaccination and measles vaccination in children with febrile convulsions: a questionnaire survey in Takamatsu City. No To Hattatsu 2001 Jul; 33(4): 336–41PubMed Miyake S, Fujita M, Endo C, et al. Recurrence of febrile convulsions after the first diphtheria-pertussis-tetanus vaccination and measles vaccination in children with febrile convulsions: a questionnaire survey in Takamatsu City. No To Hattatsu 2001 Jul; 33(4): 336–41PubMed
54.
55.
go back to reference Livingston S. Comprehensive management of epilepsy in infancy, childhood and adolescence. Springfield (IL): CC Thomas, 1972 Livingston S. Comprehensive management of epilepsy in infancy, childhood and adolescence. Springfield (IL): CC Thomas, 1972
56.
go back to reference Department of Health and Social Security. Whooping cough: reports from the Committee on the Safety of Medicines and the Joint Committee of Vaccination and Immunisation. London: Her Majesty’s Stationery Office, 1981 Department of Health and Social Security. Whooping cough: reports from the Committee on the Safety of Medicines and the Joint Committee of Vaccination and Immunisation. London: Her Majesty’s Stationery Office, 1981
57.
go back to reference Institute of Medicine. DTP vaccine and chronic nervous system dysfunction: a new analysis. Washington, DC: National Academy Press, 1994 Institute of Medicine. DTP vaccine and chronic nervous system dysfunction: a new analysis. Washington, DC: National Academy Press, 1994
58.
go back to reference Royal College of Paediatrics and Child Health. Immunisation of the immunocompromised child: best practice statement. London: RCPCH, 2002 Royal College of Paediatrics and Child Health. Immunisation of the immunocompromised child: best practice statement. London: RCPCH, 2002
59.
go back to reference Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. MMWR 2002; 51 (RR-2): 1–35 Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. MMWR 2002; 51 (RR-2): 1–35
60.
go back to reference Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1–19 Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1–19
61.
go back to reference Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81(1): 61–70PubMed Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81(1): 61–70PubMed
62.
go back to reference Expanded Programme on Immunisation. Contraindications for vaccines used in the EPI. Wkly Epidem Rec 1988; 37: 279–81 Expanded Programme on Immunisation. Contraindications for vaccines used in the EPI. Wkly Epidem Rec 1988; 37: 279–81
63.
go back to reference Varilrix™ summary of product characteristics (revised version). Uxbridge: GlaxoSmithKline, September 2004 Varilrix™ summary of product characteristics (revised version). Uxbridge: GlaxoSmithKline, September 2004
64.
go back to reference Varivax® summary of product characteristics (revised version). Maidenhead: Sanofi Pasteur MSD, March 2005 Varivax® summary of product characteristics (revised version). Maidenhead: Sanofi Pasteur MSD, March 2005
65.
go back to reference Krober MS, Stracener CE, Bass JW. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 1991 Apr 24; 265(16): 2095–6PubMedCrossRef Krober MS, Stracener CE, Bass JW. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 1991 Apr 24; 265(16): 2095–6PubMedCrossRef
66.
go back to reference Dennehy PH, Saracen CI, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994 Oct; 94(4 Pt 1): 545–7 Dennehy PH, Saracen CI, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994 Oct; 94(4 Pt 1): 545–7
67.
go back to reference King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996 Mar 6; 275(9): 704–7PubMedCrossRef King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996 Mar 6; 275(9): 704–7PubMedCrossRef
68.
go back to reference Miller E, Waight P, Farrington P, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001 Mar; 84(3): 227–9PubMedCrossRef Miller E, Waight P, Farrington P, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001 Mar; 84(3): 227–9PubMedCrossRef
69.
go back to reference Salisbury DM, Olivé J-M. Immunization in Europe. In: Plotkin S, Orenstein W, editors. Vaccines. 4th ed. Philadelphia: WB Saunders Company, 2004 Salisbury DM, Olivé J-M. Immunization in Europe. In: Plotkin S, Orenstein W, editors. Vaccines. 4th ed. Philadelphia: WB Saunders Company, 2004
70.
go back to reference Tatochenko V, Mitjushin IL. Contraindications to vaccination in the Russian Federation. J Infect Dis 2000; 181: S228–31PubMedCrossRef Tatochenko V, Mitjushin IL. Contraindications to vaccination in the Russian Federation. J Infect Dis 2000; 181: S228–31PubMedCrossRef
Metadata
Title
When Should Vaccination Be Contraindicated in Children?
Authors
Laura Lane
Arlene Reynolds
Dr Mary Ramsay
Publication date
01-09-2005
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 9/2005
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200528090-00001

Other articles of this Issue 9/2005

Drug Safety 9/2005 Go to the issue